Costo efectividad de la vacunación contra influenza en menores de 2 años y mayores de 65 años en Colombia

Porras-Ramírez, Alexandra; Alvis-Guzmán, Nelson; Rico-Mendoza, Alejandro; Alvis-Estrada, Luís; Castañeda-Orjuela, Carlos; Velandia-González, Martha; Hoz-Restrepo, Fernando De la

doi:10.1590/s0124-00642009000500002

Cited by 12 publications

(5 citation statements)

References 16 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the second scenario, we took values for GP consultation, hospitalization and mortality rates from 2 Colombian studies, 45,46 which were extrapolated to the age groups of analysis using US data from Molinari et al 38 …”

Section: Data Inputsmentioning

confidence: 99%

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America

Jamotte

Clay

Macabéo

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Annual trivalent influenza vaccines (TIV) containing 2 A strains and one B lineage have been recommended for the prevention of influenza in most of Latin American countries. However, the circulation of 2 B lineages (Victoria and Yamagata) and difficulties in predicting the predominating lineage have led to the development of quadrivalent influenza vaccines (QIV), including both B lineages. Thus, the objective was to estimate the public health impact and influenza-related costs if QIV would have been used instead of TIV in 3 Latin American countries. We used a static model over the seasons 2010–2014 in Brazil, 2007–2014 in Colombia and 2006–2014 in Panama, focusing on population groups targeted by local vaccination recommendations: young children, adults with risk factors and the elderly. In Brazil, between 2010 and 2014, using QIV instead of TIV would have avoided US$ 6,200 per 100,000 person-years in societal costs, based on 168 influenza cases, 89 consultations, 3.2 hospitalizations and 0.38 deaths per 100,000 person-years. In Colombia and Panama, these would have ranged from US$ 1,000 to 12,700 (based on 34 cases, 13–25 consultations, 0.6–8.9 hospitalizations and 0.04–1.74 deaths) and from US$ 3,000 to 33,700 (based on 113 cases, 55–82 consultations, 0.5–27.8 hospitalizations and 0.08–6.87 deaths) per 100,000 person-years, respectively. Overall, the broader protection offered by QIV would have reduced the influenza humanistic and economic burden in the 3 countries. Despite the lack of local data leading to several extrapolations, this study is the first to give quantitative estimates of the potential benefits of QIV in Latin America.

show abstract

Section: Data Inputsmentioning

confidence: 99%

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America

Jamotte

Clay

Macabéo

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…In 2007, a Colombian economic study estimated in 230 and 2500 the annual number of deaths among children <2 years and adults >65 years, respectively. 17 On average, >30 000 cases in both age groups would require in-hospital care every year. Another analysis found that general mortality increase between 2% and 11% when influenza virus circulated in Colombia.…”

Section: Introductionmentioning

confidence: 99%

Economic Cost of Severe Acute Respiratory Infection Associated to Influenza in Colombian Children: A Single Setting Analysis

Salcedo-Mejía

Alvis-Zakzuk

Carrasquilla-Sotomayor³

et al. 2019

Value in Health Regional Issues

Self Cite

View full text Add to dashboard Cite

Background: Influenza is considered a leading public health problem because its large economic burden of disease worldwide, especially in low-and middle-income countries, such as Colombia. Objective: We aimed to estimate the economic costs of influenzaconfirmed patients in a pediatric hospital in Cartagena, Colombia. Methods: We conducted a retrospective costing analysis. We estimated the direct (direct medical and out-of-pocket expenditures) and indirect costs for influenza-confirmed severe acute respiratory infection cases from a societal perspective. Total economic costs were calculated adding direct medical costs, out-of-pocket expenditures, and indirect costs owing to loss of productivity of caregivers. Mean, median, 95% confidence interval (95% CI) and interquartile range (IQR) of costs were measured. All costs are reported in USD ($1.00 ¼ COP$2000.7) Results: Forty-four cases were included in the analysis: 30 had influenza B, 10 influenza A and B, and 4 influenza AH1N1. Thirty patients were hospitalized in the general ward, 14 went to the intensive care unit. The average duration of stay was ~9 days (95% CI, 6.

show abstract

“…Over 65 years: In 23 of 25 studies, vaccination was considered cost-effective [ 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 ]. The studies were carried out with economic models in 20 countries (including eight countries in the Americas) and analyzed vaccination with trivalent vaccine, or CE of the use of high-dose trivalent, with adjuvants, or quadrivalent.…”

Section: Resultsmentioning

confidence: 99%

Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation

Liprandi

Zaidel

et al. 2021

Global Heart

View full text Add to dashboard Cite

Background: Cardiovascular mortality is decreasing but remains the leading cause of death world-wide. Respiratory infections such as influenza significantly contribute to morbidity and mortality in patients with cardiovascular disease. Despite of proven benefits, influenza vaccination is not fully implemented, especially in Latin America. Objective: The aim was to develop a regional consensus with recommendations regarding influenza vaccination and cardiovascular disease. Methods: A multidisciplinary team composed by experts in the management and prevention of cardiovascular disease from the Americas, convened by the Inter-American Society of Cardiology (IASC) and the World Heart Federation (WHF), participated in the process and the formulation of statements. The modified RAND/UCLA methodology was used. This document was supported by a grant from the WHF. Results: An extensive literature search was divided into seven questions, and a total of 23 conclusions and 29 recommendations were achieved. There was no disagreement among experts in the conclusions or recommendations. Conclusions: There is a strong correlation between influenza and cardiovascular events. Influenza vaccination is not only safe and a proven strategy to reduce cardiovascular events, but it is also cost saving. We found several barriers for its global implementation and potential strategies to overcome them.

show abstract

Costo efectividad de la vacunación contra influenza en menores de 2 años y mayores de 65 años en Colombia

Abstract: This study's results supported the Colombian Ministry of Health's initiative for introducing yearly flu vaccination amongst small children and older adults in Colombia.

Cited by 12 publications

References 16 publications

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America

Economic Cost of Severe Acute Respiratory Infection Associated to Influenza in Colombian Children: A Single Setting Analysis

Influenza Vaccination for the Prevention of Cardiovascular Disease in the Americas: Consensus document of the Inter-American Society of Cardiology and the Word Heart Federation

Contact Info

Product

Resources

About